Filament Health Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Benjamin Lightburn
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 2900 – 550 Burrard Street Burnaby BC Canada V6C 0A3
- IPO Date
- Sep 3, 2021
- Website
- filament.health
- Similar Companies
- Business
- Filament Health Corp. (OTC: FLHLF) operates as a clinical-stage natural psychedelic drug development company focused on the discovery, development, and delivery of botanical psychedelic medicines for mental health conditions and substance use disorders; its core products include PEX010 (oral psilocybin, 1mg and 25mg doses), PEX020 (oral psilocin), and PEX030 (sublingual psilocin), alongside preclinical candidates AEX010 (ayahuasca) and AEX020 (monoamine oxidase inhibitor), all derived from standardized extracts of psilocybe cubensis fruiting bodies using proprietary extraction, purification, stabilization, and formulation technologies protected by 23 granted patents and 45 pending filings. The company conducts internal clinical trials, including an FDA-authorized Phase I trial at the University of California San Francisco comparing PEX010, PEX020, and PEX030; Phase II trials for PEX010 in methamphetamine use disorder, opioid use disorder, alcohol use disorder, and post-traumatic stress disorder; and licenses its drug candidates and intellectual property to partners such as Cybin Therapeutics (depression, alcohol use disorder), ATMA Journey Centers (therapist training), NeoLumina Bioscience (eating disorders), and Reset Pharmaceuticals (demoralization syndrome), while supplying PEX010 for academic and compassionate use programs in Canada, the US, UK, EU, Australia, and Israel under its Health Canada Dealer's License and in-house GMP facility in Burnaby, British Columbia, Canada, where it was founded on June 8, 2020. Filament serves researchers, drug developers, healthcare practitioners via Health Canada's Special Access Program, and patients targeting indications like treatment-resistant depression, chronic pain, mild cognitive impairment, existential crisis, and addiction; its vertically integrated operations support production of over 2,000 therapeutic psilocybin doses monthly and exports to global partners. Recent developments include FDA authorization on July 7, 2025, for a Phase II trial of PEX010 in alcohol use disorder and PTSD among military veterans and first responders; a July 24, 2025, partnership with University College London to supply PEX010 for two Phase II trials on brain function, perception, and psychological wellbeing; first-ever EU compassionate use approval on July 31, 2025, for PEX010 in treatment-resistant depression in Germany; an exclusive global license agreement on June 17, 2025, with the University of Alabama at Birmingham for Phase II psilocybin data in cocaine use disorder; Swedish regulatory approval on June 11, 2025, for a Phase II PEX010 trial in prolonged grief disorder at Linkoping University; positive Phase II data publication on March 17, 2025, for PEX010 in alcohol use disorder; shipment of PEX010 on January 21, 2025, to the University of Wisconsin-Madison for neuroplasticity studies; voluntary delisting from CBOE Canada on May 21, 2025, and shift to OTC Pink Limited Information tier on May 28, 2025, to streamline listings; a C$961,275 unit financing closing on April 9, 2025; and ongoing joint venture Magdalena Biosciences (40% owned, formed January 9, 2023, with Jaguar Health) advancing plant-derived candidates for ADHD and other neuropsychiatric indications, including Peruvian coca leaf imports in December 2024.
Red Light Holland Completes Acquisition of Filament Health, Creating a Global Leader in Psychedelic Drug Development, Commercialization and Distribution
Red Light Holland Announces Filament Health Obtains Final Order for Proposed Arrangement
Red Light Holland Announces Filament Health Shareholder Approval of Acquisition
Red Light Holland Announces Filament Health Obtains Interim Order for Proposed Arrangement
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression
RETRANSMISSION: Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation
Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation
Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca
Filament Health unveils positive data from Phase 2 alcohol use disorder trial
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum
Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award
Filament Health secures key approvals to advance botanical psilocybin in Q2
Filament Health expands intellectual property portfolio
Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
Filament Health secures bridge financing deal
Filament Health expands substance abuse treatment studies in first quarter
Filament Health zeroes in on botanical psilocybin for substance use disorders